Founders Fund portfolio AI companies

Freenome is a high-growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease.To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas. We have raised more than $1.1 billion from leading investors like Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis and the American Cancer Society’s BrightEdge Ventures. A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.

• Post-IPO equity
• 403 employees
• Founded 2014

Ultima Genomics is unleashing the power of genomics at scale. Our mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology’s complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima’s revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth, and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century.

• Series unknown
• 309 employees
• Founded 2016

Emerald Cloud Lab® (ECL®) is the world’s leading programmable research laboratory - allowing scientists to perform experiments from anywhere in the world, 24/7, 365 days a year. Our state-of-the-art lab is controlled through a single software interface, forming a continuous workflow from experiment design to execution and analysis. With ECL handling execution in the lab, scientists can do more science - designing protocols and interpreting results. ECL maximises productivity, accuracy and scalability while minimising costs and waste production.

• Series C
• 205 employees
• Founded 2010

Synthego is a CRISPR solutions provider that enables the acceleration of life science research and development in the pursuit of improved human health.Synthego is a pioneering force in the biotechnology industry, dedicated to advancing the frontiers of CRISPR cell and gene therapies through cutting-edge CRISPR technology and expertise. Our mission is to provide unparalleled access to best-in-class CRISPR solutions at scale, empowering agility in life science research and development from discovery through clinical trials. From streamlined approaches to licensing through full technical and regulatory support from our industry-leading experts, Synthego is enabling greater access to CRISPR technology driving to improved outcomes in patient therapeutic treatments.At Synthego, our values define who we are and how we work together to shape the future of science. Ingenuity drives us to innovate and solve complex challenges in groundbreaking ways. Collaboration fuels our success, as we believe the best ideas come from diverse perspectives working together. Kindness shapes our workplace culture, fostering mutual respect and care for one another. Empowerment inspires every team member to take initiative, grow, and make meaningful contributions. Integrity forms the foundation of everything we do, ensuring trust, transparency, and excellence guide our actions.We believe that fostering an environment of belonging is essential to driving innovation and collaboration. Through our Diversity Network Association (DNA), we actively amplify diverse voices, champion equity, and create spaces where inclusivity thrives. These principles are not just policies or initiatives; they’re integrated into our DNA and guide how we work together every day. By weaving diversity, equity, and inclusion into the fabric of our identity, we strengthen our team, inspire new ideas, and ensure everyone can contribute meaningfully to shaping the future of science.

• Series E
• 174 employees
• Founded 2012

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. From licensing our platforms, to working with us as a trusted discovery service partner, we have collaborated with over 170+ partners and counting including 18 of Fortune 50 Biopharmaceutical companies to enable the discovery of their next breakthrough biologic medicines. With Alloy, you can:• Access our ever-growing stable of antibody and bispecific discovery platforms that blend in vivo and in vitro wet-lab capabilities with AI/ML. Discover with us through our services or by licensing our technologies for use in your lab.• Unlock intracellular targets with the therapeutic potential of T cell receptor (TCR) modalities through our fully integrated KeywayTM TCRm discovery service offering.• Reach genetic disease targets at the nucleic acid level with our novel AntiClasticTM ASO Format, which enhances the molecule's potency while minimizing off-target interaction and inflammatory response.• Co-build new biotechnology companies that leverage our core platforms and service capabilities with Alloy's affiliated Venture Studio, 82VS. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA, with labs in Cambridge, U.K.; Basel, CH; and Athens, GA. We reinvest 100% of our revenue back into innovation and access to innovation.Reach out, follow, and visit our website, to learn more about how we can make better medicines, together.https://www.alloytx.com/

• Series E
• 146 employees
• Founded 2017